Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Investor Presentation (November 2026)
35 slides from Vivani Medical's investor presentation, Nov 16, 2026
Slide 1: Vivani Medical, Inc.
Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. www.vivani.com November 16, 2026
Slide 2: Disclaimers
Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe ha
Slide 3: Vivani Medical, Inc.
Vivani Medical, Inc. Miniature implants dosed once or twice a year, designed to Nasdaq: VANI address the adherence and tolerability barriers that limit GLP-1 Phase 1 SLIM-1 trial completed therapy today - Strong safety and tolerability profile observed for NPM-139 - Encouraging delivery profile Our
Slide 4: The opportunity
The opportunity Why longer-acting GLP-1 therapy matters 01 The opportunity 02 NanoPortal technology 03 SLIM-1 clinical results 04 What comes next
Slide 5: NPM-139 is designed to address adherence and tolerability barriers to sustained GLP-1 therapy
NPM-139 is designed to address adherence and tolerability barriers to sustained GLP-1 therapy A removable, once- or twice-yearly subdermal semaglutide implant for chronic weight management Real-World GI Intolerability Adherence Gaps Existing GLP-1 Treatments1: Existing GLP-1 Treatments: >50% of pati
Slide 6: Most patients discontinue GLP-1 therapy within one year
Most patients discontinue GLP-1 therapy within one Large Retrospective Cohort Study* (N=1,911) year, limiting long-term 6 months 12 months benefits 100% Illustrative Scenario** : Percent Remaining on Therapy 75% 50%+ improvement could translate to meaningfully improved patient outcomes 50% Real-worl
Slide 7: GI side effects drive substantial levels of medical discontinuation of GLP-1 therapy
GI side effects drive substantial levels of medical discontinuation of GLP-1 therapy Nausea, vomiting and diarrhea are reported by a large share of patients across approved and late-stage GLP-1 therapies 25–44% 8–24% 9–30% Nausea Vomiting Diarrhea Reported across approved and late- Most frequent dur
Slide 8: GLP-1 (semaglutide) discontinuation leads to rapid hunger-induced weight rebound
GLP-1 (semaglutide) discontinuation leads to rapid hunger- induced weight rebound Sudden semaglutide withdrawal produces immediate rebound hunger, leading to rapid weight regain mediated by greater food consumption NPM-139 semaglutide implant is designed to keep STEP 1 Extension: Semaglutide Withdra
Slide 9: Large pharma is investing heavily in extending GLP-1 dosing intervals
Large pharma is investing heavily in extending GLP-1 dosing intervals Approved GLP-1s are Recent investments target Vivani is developing once- or dosed daily or weekly monthly and beyond twice-yearly dosing APPROVED TODAY WHERE PHARMA IS INVESTING (SELECT TRANSACTIONS) VIVANI NANOPORTAL (IN DEVELOPM
Slide 10: NanoPortal technology
NanoPortal technology Pipeline, implant design, and preclinical data 01 The opportunity 02 NanoPortal technology 03 SLIM-1 clinical results 04 What comes next
Slide 11: Company pipeline utilizing NanoPortal platform
Company pipeline utilizing NanoPortal platform If approved, Vivani products would provide a differentiated ultra-long-acting option for patients Indication Feasibility Preclinical Clinical Obesity/Weight NPM-139 Management semaglutide Type 2 Vivani NPM-133 Diabetes semaglutide Obesity/Weight Next-ge
Slide 12: NanoPortal: Good things come in small packages
NanoPortal: Good things come in small packages 01 GLP-1 implant & applicator 02 NanoPortal device elements 03 NanoPortal technology ✔ Biocompatible materials ✔ Nanotube pore size is precisely tunable to achieve near-constant release ✔ Designed to assure adherence profiles ✔ Long-term delivery ✔ Stab
Slide 13: Proprietary NanoPortal implant technology delivers smooth, near-constant drug release
Proprietary NanoPortal implant technology delivers smooth, near- constant drug release Six-month configuration avoiding peaks and troughs associated with orals, injectables and missed dosing In vitro exenatide release-rate. Day 1 timepoint includes cumulative release over the first day including a s
Slide 14: Prototype NPM-139 demonstrates sustained weight loss and delivery for a full year
Prototype NPM-139 demonstrates sustained weight loss and delivery for a full year A B explanted devices Prototype NPM-139 (semaglutide implant), prior to PK Normalized semaglutide plasma concentrations remain optimization. In Vivo Pharmacokinetics and Weight loss measurable throughout the entire 364
Slide 15: NPM-139 provides steady preclinical pharmacokinetics
NPM-139 provides steady preclinical pharmacokinetics In vivo pharmacokinetics of NPM-139 (semaglutide implant) configurations in Sprague-Dawley rats. Values are mean ± SE. *n=5 through day 28; two implants removed at Day 28 for characterization, n=3 thereafter. NPM-139 Configuration 1 study ended at
Slide 16: NanoPortal platform potential beyond semaglutide: prototype retatrutide implant
NanoPortal platform potential beyond semaglutide: prototype Prototype NanoPortal Retatrutide Implant, retatrutide implant n=12 (through day 28), n=9 (day 28 to 56), n=6 thereafter The NanoPortal pipeline includes a number of next-generation incretins (more potent and/or multi-agonists), including re
Slide 17: SLIM-1 clinical results
SLIM-1 clinical results First study in people of the NPM-139 semaglutide implant 01 The opportunity 02 NanoPortal technology 03 SLIM-1 clinical results 04 What comes next
Slide 18: NPM-139 Phase 1 study design: SLIM-1
NPM-139 Phase 1 study design: SLIM-1 Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerability assessment and pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization Otherwise healthy (no T2D) Screen and Treatment (4 Weeks) EOT Randomize (~21 days) NPM-139 (se
Slide 19: SLIM-1 top-line results at a glance
SLIM-1 top-line results at a glance First-in-human study: Low-dose NPM-139 implant vs. Wegovy® 0.25 mg weekly in 20 adults over 4 weeks TOLERABILITY DRUG RELEASE NEXT STEP 0 TRAEs 0 Burst 2027 Phase 2 No NPM-139 participants Desirability of gradual drug Phase 2 dose-ranging weight experienced advers
Slide 20: Strong Gastrointestinal Safety and Tolerability Profile for NPM-139
Strong Gastrointestinal Safety and Tolerability Profile for NPM-139 Single treatment-emergent All treatment-emergent GI AEs in the SC GI AE in the implant group group (Wegovy) were reported as (NPM-139) was reported as treatment-related except for the single not treatment-related case of diarrhoea 0
Slide 21: Strong Overall Safety and Tolerability Profile for NPM-139
Strong Overall Safety and Tolerability Profile for NPM-139 Chlorhexidine skin reactions (n=2): rash confined to the area where chlorhexidine antiseptic was applied. 0 TRAEs Zero adverse events, including 5 subjects in the SC group (Wegovy) Both fully resolved with topical hydrocortisone and an oral
Slide 22: NPM-139: no early drug exposure spike
NPM-139: no early drug exposure spike Mean semaglutide plasma levels over the 4-week SLIM-1 study (n=10 per group) 1 No rapid increase 35 First 48 hours NPM-139 stayed below the quantifiable limit Wegovy® 0.25 mg weekly for the first two days, then rose gradually. Wegovy® rises steeply; NPM-139 stay
Slide 23: Encouraging 28-Day Translation from Rats to Humans
Encouraging 28-Day Translation from Rats to Humans Expected translation of longer-duration rat data to humans supports reliability of preclinical models How to read this chart NPM-139 implant in humans (n=10) Gradual rise which peaks in weeks 2–3. Tolerability profile supports desirability of early
Slide 24: NPM-139 Weight Loss Comparable with Wegovy Control Group
NPM-139 Weight Loss Comparable with Wegovy Control Group NPM-139 subjects (n=10) lost Wegovy subjects lost an an average of 0.67 kg (0.79%) average of 0.76 kg (0.82%) 24
Slide 25: SLIM-1 Frequently Asked Questions
SLIM-1 Frequently Asked Questions Select shareholder inquiries Why did drug levels peak in weeks 2–3 and ease What is the “manufacturing subgroup”? Q Q by day 28? These 28-day data translate well from a 28-day preclinical rodent study of A subgroup of five of the ten SLIM-1 implants, selected using
Slide 26: What comes next
What comes next Development plan, SLIM-2, and the market opportunity 01 The opportunity 02 NanoPortal technology 03 SLIM-1 clinical results 04 What comes next
Slide 27: NPM-139 clinical and regulatory development: Near-term plan builds on recent wins
NPM-139 clinical and regulatory development: Near-term plan builds on recent wins RECENT WINS NEAR-TERM PLAN August 2025 Preclinical proof of concept reported for NPM-139 2027 SLIM-2 configurations June 2026 Regulatory approval received to initiate SLIM-1 Finalization of up to 6-month high- dose imp
Slide 28: Designed for long-term weight maintenance
Designed for long-term weight maintenance Weight returns when GLP-1 therapy stops, so the lasting benefit depends on staying on treatment How NPM-139 is designed to fit Why staying on therapy matters STEP 4 trial: weight change over the 48 weeks after a 20- week semaglutide run-in1 1 2 3 Reach goal
Slide 29: Proposed NPM-139 Phase 2 study design: SLIM-2
Proposed NPM-139 Phase 2 study design: SLIM-2 ~25-40 Subjects Per Group Randomize Run-In (20 weeks)* Randomized Treatment Period (16 or 24 weeks) Semaglutide Implant Dose 3 Semaglutide Implant Dose 2 2.4 mg Semaglutide Implant Dose 1 1.7 mg 1.0 mg Placebo (sham implant) 0.5 mg Semaglutide 0.25 mg We
Slide 30: Patient and prescriber market research signals strong adoption potential
Patient and prescriber market research signals strong adoption potential for an ultra-long-acting GLP-1 implant Currently on a GLP-1 therapy (n=324) Patient market research 56% of GLP-1 patients responded “likely” 11% 33% 42% 14% or “definitely” to get a GLP-1 implant if FDA approved, prescriber rec
Slide 31: Contraception analog supports strong adoption potential for an ultra-long-acting GLP-1 implant
Contraception analog supports strong adoption potential for an ultra-long-acting GLP-1 implant THE CONTRACEPTION MARKET: AN ANALOG FOR GLP-1s Both require chronic dosing, with options spanning daily oral pills and long-acting implants. Among U.S. women ages 15–49 using a prescription contraceptive d
Slide 32: The Vivani executive leadership team
The Vivani executive leadership team Donald Dwyer, MBA Lisa Porter, MD Chief Business Officer Chief Medical Officer Former Executive Director at AstraZeneca with leadership Former Chief Medical Officer for Eiger roles in regulatory affairs, drug development, commercial BioPharmaceuticals and Dan
Slide 33: Vivani headquarters and GMP manufacturing facility
Vivani headquarters and GMP manufacturing facility 33
Slide 34: Guaranteed adherence. Better outcomes.
Guaranteed adherence. Better outcomes. To our knowledge, the only once- or twice-yearly miniature GLP-1 implants in development Significant improvements in adherence, tolerability and convenience expected to address primary GLP-1 market challenges today and in the future Unique opportunity aligning
Slide 35: Thank You
Thank You Company Contact: Donald Dwyer, Chief Business Officer info@vivani.com Investor Relations Contact: Jami Taylor, Investor Relations Advisor investors@vivani.com www.vivani.com
Vivani Medical — Investor Presentation (November 2026) on 6ix